Kumar Puneet, Kumar Anil
Pharmacology Division, University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Study, Panjab University, Chandigarh, India.
Neurosci Res. 2009 Apr;63(4):302-14. doi: 10.1016/j.neures.2009.01.005.
Cyclosporine and FK506, a well-known immunosuppressant drugs that are presently being used for prevention of allograft rejection. Recently, several studies suggest their therapeutic potential in the treatment of neurodegenerative diseases. Therefore, present study was conducted to explore their therapeutic potential against 3-nitropropionic acid induced cognitive dysfunctions and biochemical alterations in striatum, cortex and hippocampal regions of brain. Further, attempt has also been made to investigate their possible interaction with nitric oxide modulators.3-Nitropropionic acid (10 mg/kg) for 14 days treatment significantly impaired cognitive task as evidenced by Morris water as well as plus maze performance tasks. 3-Nitropropionic acid treatment significantly disturbed glutathione redox ratio and different levels of glutathione (as indicated by alterations in total glutathione, reduced glutathione, oxidized glutathione, glutathione-S-transferase levels). Acetylcholinesterase enzyme activity was also significantly disturbed by 3-NP treatment. Further, FK-506 (0.5, 1 and 2 mg/kg, p.o.) and cyclosporine (2.5, 5 and 10 mg/kg, p.o.) treatment significantly improved cognitive functions both in Morris water maze and plus maze tasks. Beside these drug treatment significantly attenuated oxidative stress as evidenced by restoring different glutathione levels and acetylcholinesterase activity as compared to control (3-NP treated) animals. Further sub effective doses of cyclosporine (5 mg/kg) and FK-506 (1 mg/kg) effect was potentated by l-NAME and reversed by l-arginine pretreatment. The effects were significant as compared to their effect per se.Study highlights the therapeutic potential of these drugs in the treatment of Huntington's disease. Study further suggest that nitric oxide modulation in involved in the neuroprotective effect of these drugs against 3-NP neurotoxicity.
环孢素和FK506是目前用于预防同种异体移植排斥反应的著名免疫抑制剂药物。最近,多项研究表明它们在治疗神经退行性疾病方面具有治疗潜力。因此,本研究旨在探讨它们对3-硝基丙酸诱导的脑纹状体、皮质和海马区域认知功能障碍及生化改变的治疗潜力。此外,还尝试研究它们与一氧化氮调节剂的可能相互作用。14天的3-硝基丙酸(10毫克/千克)治疗显著损害了认知任务,莫里斯水迷宫以及加迷宫性能任务证明了这一点。3-硝基丙酸治疗显著扰乱了谷胱甘肽氧化还原比和不同水平的谷胱甘肽(总谷胱甘肽、还原型谷胱甘肽、氧化型谷胱甘肽、谷胱甘肽-S-转移酶水平的改变表明)。3-NP治疗也显著扰乱了乙酰胆碱酯酶的活性。此外,FK-506(0.5、1和2毫克/千克,口服)和环孢素(2.5、5和10毫克/千克,口服)治疗在莫里斯水迷宫和加迷宫任务中均显著改善了认知功能。除了这些药物治疗外,与对照(3-NP处理)动物相比,通过恢复不同的谷胱甘肽水平和乙酰胆碱酯酶活性,显著减轻了氧化应激。此外,环孢素(5毫克/千克)和FK-506(1毫克/千克)的亚有效剂量的作用通过L-NAME增强,并通过L-精氨酸预处理逆转。与它们本身的作用相比,这些作用是显著的。该研究突出了这些药物在治疗亨廷顿舞蹈病方面的治疗潜力。该研究进一步表明,一氧化氮调节参与了这些药物对3-NP神经毒性的神经保护作用。